<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Allarity Therapeutics Inc — News on 6ix</title>
    <link>https://6ix.com/company/allarity-therapeutics-inc</link>
    <description>Latest news and press releases for Allarity Therapeutics Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 27 Apr 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/allarity-therapeutics-inc" rel="self" type="application/rss+xml" />
    <item>
      <title>Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-announces-that-the-stenoparib-drpr-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-announces-that-the-stenoparib-drpr-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office</guid>
      <pubDate>Mon, 27 Apr 2026 12:00:00 GMT</pubDate>
      <description>Patent expected to be formally granted within three months, subject to standard administrative proceduresPatent would provide exclusivity at least into 2039 for stenoparib when used in concert with the stenoparib DRP test TARPON SPRINGS, Fla., April 27, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced th</description>
    </item>
    <item>
      <title>Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-presents-two-aacr-2026-posters-highlighting-stenoparibs-potential-in-colorectal-cancer-as-well-as-new-predictive-data-linking-drpr-and-overall-survival-in-ovarian-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-presents-two-aacr-2026-posters-highlighting-stenoparibs-potential-in-colorectal-cancer-as-well-as-new-predictive-data-linking-drpr-and-overall-survival-in-ovarian-cancer</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 GMT</pubDate>
      <description>New AACR data highlight stenoparib’s potential in colorectal cancer through WNT pathway modulationThe Stenoparib-DRP® companion diagnostic is associated with enhanced overall survival in Ovarian Cancer patientsPosters now available on Allarity’s website TARPON SPRINGS, Fla., April 21, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathw</description>
    </item>
    <item>
      <title>Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-reports-full-year-2025-financial-results-and-corporate-progress</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-reports-full-year-2025-financial-results-and-corporate-progress</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA</description>
    </item>
    <item>
      <title>Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-closes-dollar20-million-financing-to-accelerate-the-advance-of-stenoparib-toward-fda-approval-and-commercialization-35</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-closes-dollar20-million-financing-to-accelerate-the-advance-of-stenoparib-toward-fda-approval-and-commercialization-35</guid>
      <pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
      <description>Extends Company Cash Runway into Mid-2028Financing Expected to Fund Completion of Phase 2 Ovarian Cancer TrialFinancing Supports Acceleration Toward Pivotal</description>
    </item>
    <item>
      <title>Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-doses-first-patients-131500709</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-doses-first-patients-131500709</guid>
      <pubDate>Wed, 18 Feb 2026 13:15:00 GMT</pubDate>
      <description>Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by the U.S. Department of Veterans Affairs and is open for enrollment at 11 VA sites nationwide Relapsed SCLC remains an area of high unmet need without effective treatment options TARPON SPRINGS, Fla., February 18, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to develo</description>
    </item>
    <item>
      <title>Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-announces-collaborative-phase-130000222</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-announces-collaborative-phase-130000222</guid>
      <pubDate>Tue, 03 Feb 2026 13:00:00 GMT</pubDate>
      <description>This is the first trial combining Allarity’s stenoparib with another anti-cancer agent Stenoparib’s favorable safety profile supports potential for use in combination regimens Trial is fully funded by the U.S. Department of Veterans Affairs and is open to enrollment at 11 VA sites throughout the US TARPON SPRINGS, Fla., February 3, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2</description>
    </item>
    <item>
      <title>Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-issues-2025-end-130000193</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-issues-2025-end-130000193</guid>
      <pubDate>Wed, 31 Dec 2025 13:00:00 GMT</pubDate>
      <description>TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today issued the following letter to shareholders from the Company’s Chief Executive Officer.Dear Shareholders, As we close out 2025, I write to you with both optimism and gratitude. Your continued support has helped steer Allarity Therap</description>
    </item>
    <item>
      <title>Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-provides-third-quarter-140000832</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-provides-third-quarter-140000832</guid>
      <pubDate>Fri, 14 Nov 2025 14:00:00 GMT</pubDate>
      <description>Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trialAdvanced DRP® platform through new licensing agreement TARPON SPRINGS, Fla., November 14, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported</description>
    </item>
    <item>
      <title>Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-presents-phase-2-120000220</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-presents-phase-2-120000220</guid>
      <pubDate>Mon, 22 Sep 2025 12:00:00 GMT</pubDate>
      <description>- Kaplan-Meier analyses show for the first time that median Overall Survival exceeds 25 months for Platinum Resistant and Refractory Ovarian Cancer Patients receiving stenoparib/2X-121 twice daily - Two patients continue on therapy now more than 24 months - Clinical Benefit Evident in patients with BRCAwt as well as BRCAmut genetics - Data presented at the American Association for Cancer Research (AACR) 7th Biennial Special Conference on Ovarian Cancer, Denver CO TARPON SPRINGS, Fla., September</description>
    </item>
    <item>
      <title>Allarity Therapeutics CEO to Present at Biomarkers &amp; Precision Medicine 2025</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-ceo-present-biomarkers-120000214</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-ceo-present-biomarkers-120000214</guid>
      <pubDate>Wed, 17 Sep 2025 12:00:00 GMT</pubDate>
      <description>TARPON SPRINGS, Fla., September 17, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced that its CEO, Thomas Jensen, has been invited to present at the upcoming Biomarkers &amp; Precision Medicine 2025 conference in London, organized by Oxford Global. In addition to his presentation, Mr. Jensen will be interviewed by Oxf</description>
    </item>
    <item>
      <title>Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-granted-fda-fast-120000019</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-granted-fda-fast-120000019</guid>
      <pubDate>Tue, 26 Aug 2025 12:00:00 GMT</pubDate>
      <description>TARPON SPRINGS, Fla., August 26, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to stenoparib, its investigational treatment for patients with advanced ovarian cancer. The FDA’s Fast Track designation is intended to expedite the</description>
    </item>
    <item>
      <title>Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-provides-second-quarter-203000773</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-provides-second-quarter-203000773</guid>
      <pubDate>Fri, 15 Aug 2025 20:30:00 GMT</pubDate>
      <description>- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP® companion diagnostic- Secured new service contract with EU biotech for Allarity Medical Laboratory TARPON SPRINGS, Fla., August 15, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP a</description>
    </item>
    <item>
      <title>Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-announces-licensing-laboratory-120000940</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-announces-licensing-laboratory-120000940</guid>
      <pubDate>Tue, 15 Jul 2025 12:00:00 GMT</pubDate>
      <description>TARPON SPRINGS, Fla., July 15, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor, today announced the signing of a new commercial agreement with a non-disclosed EU-based biotechnology company. The agreement provides the partner with a non-exclusive global license to a range of selected proprietary Allarity DRP® algorithms in brea</description>
    </item>
    <item>
      <title>Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-announces-appointment-jeff-120000175</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-announces-appointment-jeff-120000175</guid>
      <pubDate>Mon, 07 Jul 2025 12:00:00 GMT</pubDate>
      <description>TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology, today announced the appointment of Jeff Ervin as the Company’s new Chief Financial Officer (CFO). He succeeds Alexande</description>
    </item>
    <item>
      <title>Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-receives-australian-patent-120000173</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-receives-australian-patent-120000173</guid>
      <pubDate>Mon, 30 Jun 2025 12:00:00 GMT</pubDate>
      <description>TARPON SPRINGS, Fla., June 30, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that IP Australia, the Australian Government agency that administers intellectual property rights in t</description>
    </item>
    <item>
      <title>Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-announces-dosing-second-120000344</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-announces-dosing-second-120000344</guid>
      <pubDate>Fri, 27 Jun 2025 12:00:00 GMT</pubDate>
      <description>TARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor today announced that the second patient has been dosed in its new Phase 2 clinical trial protocol evaluating stenoparib in patients with advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer. Commenting on the development, Tho</description>
    </item>
    <item>
      <title>Allarity Therapeutics Announces Changes to Board of Directors</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-announces-changes-board-200500637</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-announces-changes-board-200500637</guid>
      <pubDate>Wed, 11 Jun 2025 20:05:00 GMT</pubDate>
      <description>TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company’s Board of Directors. He will be replacing</description>
    </item>
    <item>
      <title>Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-announces-research-collaboration-120000202</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-announces-research-collaboration-120000202</guid>
      <pubDate>Wed, 04 Jun 2025 12:00:00 GMT</pubDate>
      <description>TARPON SPRINGS, Fla., June 4, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced a research collaboration with the Indiana Biosciences Research Institute (IBRI). The collaboration is a</description>
    </item>
    <item>
      <title>Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-announces-first-patient-120000390</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-announces-first-patient-120000390</guid>
      <pubDate>Mon, 02 Jun 2025 12:00:00 GMT</pubDate>
      <description>TARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the first patient has been enrolled in its new Phase 2 clinical trial protocol of stenoparib for the treatment of advanced, platinum-resistant or platinum-ineligible ovarian cancer. The newly launched protocol will accelerate the</description>
    </item>
    <item>
      <title>Allarity Therapeutics Announces Participation in Pharma Partnering Summit US</title>
      <link>https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-announces-participation-pharma-120000079</link>
      <guid isPermaLink="true">https://6ix.com/company/allarity-therapeutics-inc/news/allarity-therapeutics-announces-participation-pharma-120000079</guid>
      <pubDate>Mon, 12 May 2025 12:00:00 GMT</pubDate>
      <description>TARPON SPRINGS, Fla., May 12, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced the Company’s CEO, Thomas Jensen, will deliver a company overview focused on stenoparib and the Company’s DRP® companion diagnostic platform and conduct one-on-one meetings at the Pharma Partnering Summit US. The event is a business de</description>
    </item>
  </channel>
</rss>